Defining and Striving for HBV Cure: What’s in the Pipeline

CCO Infectious Disease Podcast

English - June 30, 2022 16:05 - 14 minutes - 13.5 MB
Courses Education Science Life Sciences hiv covid-19 cme hepatitis b hbv id medical education coronavirus hepatitis c hcv Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: My Perspective: Living With HIV Is Life Changing but Not Life Limiting

Next Episode: Advancements in Viral Hepatitis From EASL 2022

In this episode, Carla S. Coffin, MD, MSc, shares her thoughts on the different investigational approaches under evaluation for their potential to achieve HBV cure, including entry inhibitors, capsid inhibitors, siRNAs, immune modulators, TLR agonists, therapeutic vaccines, and checkpoint inhibitors.

Presenter:

Carla S. Coffin, MD, MSc
Professor of Medicine
Division of Gastroenterology and Hepatology
Department of Medicine
University of Calgary
Medical Director of Calgary Liver Unit
Division of Gastroenterology and Hepatology
Department of Medicine
Foothills Medical Centre
Calgary, Alberta, Canada

Content based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences, Inc. and developed in collaboration with the American Liver Foundation.

Link to full program:
https://bit.ly/3OGHvOv